[3] After his postdoctoral work at MIT, in 1997 De Rubertis moved back to Geneva, where he joined Index Ventures and helped co-found the firm's life sciences practice.
[12] Medicxi is managed by four Partners Francesco de Rubertis, Kevin Johnson, David Grainger and Michèle Ollier all of whom previously led the Life Sciences practice at Index Ventures.
He was selected as one of 10 nominees in the Tech (& Science) category along with Elon Musk (Tesla, SpaceX), Masayoshi Son (SoftBank Group) and Martin Lau (Tencent Holdings).
De Rubertis's reputation for halving the time it takes for a return on biotech investments has Silicon Valley eager to get in on a $300 million fund he's raised for late-stage startups.
Medicxi Growth 1, which made its first investments in health care and diabetes treatments, is taking minority stakes in companies that are developing multiple therapies, have full management teams, and intend to go public as independent businesses.